-
MEXIDOL® (Emoxipine) 125 mg, 50 coated tablets
$17.00
$22.00 -
ARPEFLU (Umifenovir) 100 mg, 20/30 caps
$24.00 – $33.00
Description
The instruction for medical use
of Hondroksid Torgovoye medicine a name
Hondroksid
Mezhdunarodnoye the unlicensed name
Is not present
the Dosage form
Ointment for external use of 5%
Structure
of 1 g of ointment contains
active agent – sodium sulfate chondroitin (in terms of 100% substance) 0.05 g
excipients: a dimethyl sulfoxide (Dimexidum), lanolin (lanolin anhydrous, wax woolen), the vaseline, monoglycerides distilled the water purified.
The description
Ointment of light yellow color with a dimethyl sulfoxide smell.
Pharmacotherapeutic group
Other drugs for topical treatment of diseases of the musculoskeletal system.
The code of automatic telephone exchange
the Pharmacological
Pharmacokinetics properties
Hondroksid ointment is well soaked up by M02AX. According to the data obtained in pilot studies on mice with use of radio marked 3H-chondroitin of sulfate, the rate of absorbability of chondroitin of sulfate is 14%. The dimethyl sulfoxide promotes the best penetration of chondroitin of sulfate through cellular membranes deep into of fabrics. Chondroitin sulfate, after putting drug Hondroksid ointment on skin, quickly and selectively comes to a joint with achievement of the maximum concentration in 30 minutes and the subsequent two-phase removal of drug from cartilaginous tissue. End of a fast phase of removal happens in 1 hour after use. Time of deduction of drug in a joint is 5 hours.
The pharmacodynamics
the Main active ingredient of drug is chondroitin sulfate – the high-molecular mucopolysaccharide which is slowing down a resorption of a bone tissue and reducing calcium loss. Chondroitin sulfate improves phosphorus-calcium exchange in cartilaginous tissue, accelerates processes of recovery of a bone tissue, slows down processes of a degeneration (destruction) of cartilaginous tissue. Interferes with collapse of connective tissue, inhibits the enzymes causing damage to cartilaginous tissue, stimulates synthesis of glucosaminoglycans, promotes regeneration (restoration) of an articulate bag and the cartilaginous surfaces of joints, increases products of intra articulate liquid. Slows down progressing of an osteoarthrosis and osteochondrosis, normalizes a metabolism in hyaline fabric, has anesthetic and anti-inflammatory effect. It leads to increase in mobility of the affected joints.
The dimethyl sulfoxide which is a part of ointment has anti-inflammatory, analgetic and fibrinolytic effect, the best penetration is promoted by sulfate chondroitin through cellular membranes.
Indications
– degenerative dystrophic diseases of joints and a backbone (treatment and prevention of an osteoarthrosis, osteoarthrosis of a temporal and mandibular joint, a spondylarthrosis, osteochondrosis, osteoporosis, a heyroartropatiya)
the Route of administration and doses
Outwardly. Ointment Hondroksid is applied by 2-3 times a day to skin over the center of defeat and rub within 2-3 minutes before full absorption. A course of treatment – from 2-3 weeks to 2-3 months. If necessary the course of treatment is repeated.
Side effects
– allergic reactions.
Contraindications
– hypersensitivity to drug components
– damage of integuments in the field of putting drug
Medicinal interactions
Cases of interaction or incompatibility with other medicines are not described.
Special instructions
It is necessary to avoid hit of drug on mucous membranes and open wounds.
Children’s age
the Efficiency and safety of use of Hondroksid at children’s age are not established.
Pregnancy and a lactation
Use during pregnancy and a lactation is possible when the expected advantage of use of drug for mother exceeds potential risk
for a fruit or the child.
The feature of influence of medicine on ability to drive the car or potentially dangerous mechanisms
does not influence ability to drive the car or potentially dangerous mechanisms.
Overdose
About drug HondroksidÒ overdose cases, ointment it was not reported.
A form of release and packing
On 30 g in tubas aluminum.
Each tuba together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard.
To Store storage conditions at
a temperature not higher than 25 S. Hranit out of children’s reach!
A period of storage
3 years
not to use drug after an expiration date.
Prescription status
Without prescription
JSC Nizhpharm Producer,
Russian Federation 603950, Nizhny Novgorod, GSP-459, Salganskaya St., 7
ph.: (831) 278-80-88
fax: (831) 430-72-28
a web the website: http://www.nizhpharm.ru
the Name and the country of the owner of the registration certificate
of JSC Nizhpharm, the Russian Federation
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)
Representative office of JSC Nizhpharm
050043, Republic of Kazakhstan, Almaty, mdt. Khan-Taniri, 55b
ph.: (727) 271-99-68
fax: (727) 255-33-78
email: almaty@stada.kz
Additional information
| Ingredient |
|---|
Reviews
There are no reviews yet.